CFG
ADPT icon

Citizens Financial Group’s Adaptive Biotechnologies ADPT Stock Holding History

Citizens Financial Group’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$364K Buy
16,986
+445
+3% +$6.82K ﹤0.01% 774
2026
Q1 		$230K Buy
16,541
+1,800
+12% +$28.7K ﹤0.01% 765
2025
Q4 		$239K Hold
14,741
– – ﹤0.01% 733
2025
Q3 		$221K Sell
14,741
-35
-0.2% -$426 ﹤0.01% 742
2025
Q2 		$172K Buy
+14,776
New +$134K ﹤0.01% 675

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Citizens Financial Group's ADPT Position: Q2 2026 in Review

Citizens Financial Group increased its Adaptive Biotechnologies (ADPT) stake by 2.7% in Q2 2026, buying an estimated $6.82K and bringing the position to 16,986 shares worth $364K. The position accounts for ﹤0.01% of the portfolio, ranked #774.

Citizens Financial Group first reported a position in ADPT in Q2 2025 and has held it in 5 quarters since. 301 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Citizens Financial Group held 16,986 shares of Adaptive Biotechnologies worth $364K as of Q2 2026.
  • Citizens Financial Group bought 445 Adaptive Biotechnologies shares in Q2 2026, an estimated $6.82K.
  • Adaptive Biotechnologies made up ﹤0.01% of Citizens Financial Group's portfolio in Q2 2026, its #774 holding.
  • Citizens Financial Group first reported a position in Adaptive Biotechnologies in Q2 2025 and has held it in 5 quarters since.
  • 301 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Citizens Financial Group's 13F filing for Q2 2026, filed 7 Aug 2026.